Small Molecules
21 February 2013
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma Trial21 February 2013
Neurovance Receives Notice of Allowance for Composition of Matter Patent and Initiates Clinical Trial of New SR Formulation of EB-102021 February 2013
Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia21 February 2013
Alexza Receives Marketing Authorization for ADASUVE® (Staccato Loxapine) in the European Union19 February 2013
Edison Pharmaceuticals & Bambino Gesu Children’s Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial19 February 2013
Data Demonstrating the Safety and Efficacy of Chimerix’s Antiviral CMX001 Presented at BMT Tandem Meetings19 February 2013
GSK and Theravance Announce FDA Acceptance of New Drug Application (NDA) Submission in the US for ANORO ELLIPTA(TM) for COPD19 February 2013
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease19 February 2013
Gilead’s Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study19 February 2013
BioMarin Announces Kuvan Significantly Improves Inattentiveness in Kuvan Responding PKU Patients18 February 2013
Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia18 February 2013
Novartis drug Zortress is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients15 February 2013
Medical Imaging Drugs Advisory Committee Recommends Approval of Guerbet NDA for Dotarem (gadoterate meglumine)15 February 2013
Algeta ASA : Further sub-analyses of ALSYMPCA phase III study presented at 2013 Genitourinary Cancers Symposium15 February 2013
Promising Preclinical and Phase I Data of a New Generation Androgen Receptor (AR) Inhibitor, ODM- 201, Presented at ASCO GU 2013 Symposium15 February 2013
Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium15 February 2013
Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease14 February 2013
Scioderm’s Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA14 February 2013
Auris Medical completes enrolment in TACTT1 study with AM-101 for the treatment of acute peripheral tinnitus13 February 2013
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration13 February 2013
Radium-223 Dichloride Granted Priority Review by U.S. FDA12 February 2013
Phase 3 Trial of ZIOPHARM’S Palifosfamide in First-Line Metastatic Soft Tissue Sarcoma Reaches Target Number of Progression-Free Survival Events11 February 2013
Catabasis Announces Positive Phase 1 Data for CAT-1004 Validating the SMART Linker Technology Platform11 February 2013
Celgene Provides REVLIMID Regulatory Update11 February 2013
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports